Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

d clinical development positions for Novartis Pharma. Dr. Scaife began his career as the Regulatory and Medical Affairs Manager at Johnson & Johnson Medical Ltd., UK.

Dr. Scaife received a Ph.D. in Toxicology from Leicester School of Pharmacy, United Kingdom and a B.S. degree in Pharmacology from the University of Bath, United Kingdom.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing and completion of clinical trials of Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... The “Global Diagnostic Electrocardiograph (ECG) Market by Product ... Research Center, Physician Office, Nursing Homes), by Lead ... provides a detailed overview of the major drivers, ... impacting the global diagnostic ECG market along with ... share analysis. , The global diagnostic ECG market ...
(Date:10/17/2014)... For the seventh consecutive year, ... in today’s print issue of Science magazine. , ... Survey polled employees in the biotechnology, pharmaceutical and ... Rankings were determined based on responses from ... companies on 23 characteristics, including financial strength, leadership ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The Europe ... additives market in Europe with analysis and forecast of ... Fuel Additives Market report, to get an idea of ... of the segmentation in the European fuel additives market, ... , http://www.micromarketmonitor.com/market/europe-fuel-additives-5379768082.html , Fuel additives are chemicals ...
(Date:10/17/2014)... The North American flexible display market ... America with analysis and forecast of revenue. This market ... expected to reach $1329.6 million by 2018, at a ... through the TOC of the North American flexible display ... analysis provided. This also provides a glimpse of the ...
Breaking Biology Technology:The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5DuPont Named Top Employer by Science Magazine 2DuPont Named Top Employer by Science Magazine 3The Europe Fuel Additives Market is estimated to grow to $1,401.4 million by 2018 - New Report by MicroMarket Monitor 2The Europe Fuel Additives Market is estimated to grow to $1,401.4 million by 2018 - New Report by MicroMarket Monitor 3The Europe Fuel Additives Market is estimated to grow to $1,401.4 million by 2018 - New Report by MicroMarket Monitor 4The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 3
... Sentry to Store and Distribute 500,000 Doses of the ... Strategic Reserve of the Influenza ... Solutions,announced today that The Centers for Disease Control & ... of its national,strategic reserve of the influenza virus vaccine. ...
... Company Launches First-Ever Direct-To-Consumer Campaign of a Living ... ... 11 Organogenesis, Inc., the first,company to successfully mass-produce living ... first-ever direct-to-consumer,(DTC) educational campaign for a living cell-based therapy. As ...
... OraQuick(R) HCV ... Test Outside the United States -, KENILWORTH, N.J., ... SGP ) and OraSure Technologies, Inc. (Nasdaq:,OSUR) today announced an ... oral hepatitis C virus (HCV) test utilizing OraSure,Technologies, OraQuick(R) technology ...
Cached Biology Technology:The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 2The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions 3Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 2Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 3Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 4Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 2Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 3Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 4Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test 5
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... sequenced the house fly genome for the first time, ... an insect that thrives in pathogen-rich dung piles and ... the journal Genome Biology , will increase understanding ... flies quickly adapt to resist insecticides, which could lead ... domestica) carry and transmit more than 100 human and ...
(Date:10/14/2014)... MA – A team of scientists led by ... (UMMS) and the University of Miami Miller School ... a key genetic pathway underlying bipolar (manic depressive) ... drugs for treating bipolar affective disorder, as well ... The new findings, published online this week in ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... oaks and other forests in lowland areas of Mediterranean mountains could ... those forest formations that are more adapted to cold and humid ... to 99%. Both scenarios could be quite possible in the 21st ... climate change on the forests of the Sistema Central and the ...
... professor in the Department of Biomedical and Chemical ... of Engineering and Computer Science (LCS) and member ... professors Rebecca Bader (BMCE and SBI), Yan-Yeung Luk ... Ramesh Raina (biology), have been awarded $2 million ...
... Pipe-in-pipe systems are now commonly used to distribute water ... made of a plastic called cross-linked polyethylene (PEX). Are these ... and odour of drinking water? Previous international studies ... an unwanted taste and odour to drinking water. It has ...
Cached Biology News:Holm oaks will gain ground in northern forests due to climate change 2Syracuse University receives $2 million from NSF 2Syracuse University receives $2 million from NSF 3
...
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
Biology Products: